Comparison of trimodality therapy and neoadjuvant chemotherapy combined with radical cystectomy for the survival of muscle-invasive bladder cancer: a population-based analysis

被引:2
|
作者
Zhou, Yi-Xin [1 ]
Hu, Qian-Cheng [2 ]
Zhu, Ya-Juan [1 ]
Mu, Xiao-Li [1 ]
Liu, Ji-Yan [1 ]
Chen, Ye [3 ]
机构
[1] Sichuan Univ, West China Hosp, Canc Ctr, Dept Biotherapy, 37 Guoxue Xiang St, Chengdu 610041, Sichuan, Peoples R China
[2] Sichuan Univ, West China Hosp, Gastr Canc Ctr, Lab Gastr Canc,Div Med Oncol,Canc Ctr, Chengdu, Peoples R China
[3] Sichuan Univ, West China Hosp, Canc Ctr, Div Abdominal Tumor Multimodal Treatment,Dept Radi, 37 Guoxue Xiang St, Chengdu 610041, Sichuan, Peoples R China
关键词
Muscle-invasive bladder cancer; Trimodality therapy; Radical cystectomy; Neoadjuvant chemotherapy; LONG-TERM OUTCOMES; QUALITY-OF-LIFE; UROTHELIAL CARCINOMA; ADJUVANT ATEZOLIZUMAB; MODALITY THERAPY; ELDERLY-PATIENTS; PHASE-III; RADIOTHERAPY; MULTICENTER; IMVIGOR010;
D O I
10.1186/s40001-023-01408-9
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background:Trimodality therapy (TMT) is a mature alternative to radical cystectomy (RC) for patients with muscle-invasive bladder cancer (MIBC) who seek to preserve their primary bladder or are inoperable due to comorbidities. To date, there has been increasing evidence of the effectiveness of TMT as an alternative to RC. In contrast, no literature has stated the effectiveness of neoadjuvant chemotherapy combined with RC (NAC + RC) compared with TMT. Objective:We aimed to compare the prognosis between patients receiving TMT and NAC + RC. Methods:The clinicopathological characteristics of patients with T2-4aN0M0 MIBC were obtained from the Surveillance, Epidemiology, and End Results (SEER) database. Univariate and multivariate Cox proportional hazards regression models and Kaplan-Meier survival curves were used for the survival analysis. Propensity-score matching (PSM) was applied to determine the differences between the two groups. The primary outcome was cancer-specific survival (CSS), and the secondary outcome was overall survival (OS). Results:In total, 1,175 patients with MIBC who underwent TMT (n = 822) or NAC + RC (n = 353) were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. After 1:1 PSM, the final patient sample included 303 pairs. The prognosis of patients receiving NAC + RC was significantly better than that of patients receiving TMT in both unmatched and matched cohorts (5-year CSS: before PSM, 75.4% vs. 50.6%, P < 0.0001; after PSM, 76.3% vs. 49.5%, P < 0.0001; 5-year OS: before PSM, 71.7% vs. 37.4%, P < 0.0001; after PSM, 71.7% vs. 31.4%, P < 0.0001). The survival advantages of NAC + RC remained remarkable in the stratified analysis of most factors after PSM. Multivariate Cox regression analysis showed that being older than 68 years old, unmarried, grade III/IV, T3-4a stage, and undergoing TMT independently correlated with poor OS. Conclusion:Thus, in this study, patients with MIBC receiving NAC + RC presented with a better prognosis than those receiving TMT.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Comparison of Laparoscopic and Open Radical Cystectomy for Muscle-Invasive Bladder Cancer
    Lisinski, Janusz
    Kienitz, Jakub
    Tousty, Piotr
    Kaczmarek, Krystian
    Leminski, Artur
    Slojewski, Marcin
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (23)
  • [42] Predictors of trimodality therapy in patients with muscle-invasive bladder cancer and effect on survival
    Yaxiong Tang
    Lede Lin
    Yunfei Xiao
    Linghao Meng
    Yujia Yang
    Xiang Li
    Clinical and Translational Oncology, 2024, 26 : 446 - 455
  • [43] Predictors of trimodality therapy in patients with muscle-invasive bladder cancer and effect on survival
    Tang, Yaxiong
    Lin, Lede
    Xiao, Yunfei
    Meng, Linghao
    Yang, Yujia
    Li, Xiang
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (02): : 446 - 455
  • [44] Conditional survival after radical cystectomy for non-metastatic muscle-invasive adenocarcinoma of the urinary bladder: A population-based analysis
    Tappero, S.
    Piccinelli, M.
    Barletta, F.
    Chierigo, F.
    Morra, S.
    R-B, Incesu
    Garcia, Cano C.
    Tian, Z.
    Parodi, S.
    Dell'Oglio, P.
    Briganti, A.
    De Cobelli, O.
    Chun, F. K. H.
    Graefen, M.
    Mirone, V
    Saad, F.
    Shariat, S.
    Suardi, N. R.
    Borghesi, M.
    Terrone, C.
    Karakiewicz, P., I
    EUROPEAN UROLOGY, 2023, 83 : S233 - S234
  • [45] The Impact of Radiation Therapy Dose on Survival in Patients with Muscle-Invasive Bladder Cancer: A Population-Based Analysis
    Korpics, M.
    Block, A. M.
    Harkenrider, M. M.
    Welsh, J. S.
    Solanki, A. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : S183 - S183
  • [46] Population-based outcomes comparing radical cystectomy with trimodal therapy for patients diagnosed with localized muscle-invasive bladder cancer.
    Dafashy, Tamer
    Phillips, Daniel
    Shan, Yong
    Hudgins, Hogan K.
    Jazzar, Usama
    Ray-Zack, Mohamed Danny
    Kaul, Sapna
    Kerr, Preston
    Kamat, Ashish M.
    Tyler, Douglas S.
    Freedland, Stephen J.
    Swanson, Todd A.
    Mehta, Hemalkumar B.
    Williams, Stephen Bentley
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [47] NEOADJUVANT (NACT) AND ADJUVANT CHEMOTHERAPY (ACT) FOR MUSCLE-INVASIVE BLADDER CANCER: A POPULATION-BASED OUTCOMES STUDY
    Booth, C. M.
    Siemens, D. R.
    Li, G.
    Peng, Y.
    Tannock, I. F.
    Berman, D. M.
    Kong, W.
    Mackillop, W. J.
    ANNALS OF ONCOLOGY, 2012, 23 : 260 - 260
  • [48] Delays in radical cystectomy for muscle-invasive bladder cancer
    Chu, Alice T.
    Holt, Sarah K.
    Wright, Jonathan L.
    Ramos, Jorge D.
    Grivas, Petros
    Yu, Evan Y.
    Gore, John L.
    CANCER, 2019, 125 (12) : 2011 - 2017
  • [49] Cisplatin Neoadjuvant Chemotherapy in an Aging Population With Muscle-Invasive Bladder Cancer
    Gong, Jun
    ONCOLOGY-NEW YORK, 2022, 36 (01): : 30 - 31
  • [50] Neoadjuvant Chemotherapy Before Radical Cystectomy for Muscle-Invasive Bladder Cancer: Elective and Eligibility Factors Impacting Utilization
    Patel, Hiten D.
    Naha, Ushasi
    Chen, Victor S.
    Ko, Caitlyn
    Yang, Rachel
    Druck, Aleksander
    Rac, Goran
    Ellis, Jeffrey L.
    Gupta, Gopal N.
    Woods, Michael E.
    Gorbonos, Alex
    Flanigan, Robert
    Quek, Marcus L.
    UROLOGY PRACTICE, 2024, 11 (01) : 136 - 144